SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 11.1% – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price shot up 11.1% on Thursday . The company traded as high as $7.19 and last traded at $7.2550. 8,457,704 shares were traded during trading, an increase of 12% from the average session volume of 7,522,891 shares. The stock had previously closed at $6.53.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group lifted their price target on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, SELLAS Life Sciences Group presently has a consensus rating of “Hold” and an average target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The stock has a market capitalization of $1.37 billion, a PE ratio of -32.33 and a beta of 2.24. The company’s fifty day simple moving average is $4.98 and its two-hundred day simple moving average is $3.67.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of SELLAS Life Sciences Group by 2.8% during the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after acquiring an additional 185,106 shares during the last quarter. Anson Funds Management LP lifted its holdings in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock valued at $9,713,000 after purchasing an additional 5,757,938 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of SELLAS Life Sciences Group by 35.9% during the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock worth $11,604,000 after purchasing an additional 812,953 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of SELLAS Life Sciences Group by 23,550.0% during the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock worth $5,947,000 after purchasing an additional 2,704,007 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of SELLAS Life Sciences Group by 60.8% during the fourth quarter. State Street Corp now owns 2,188,171 shares of the company’s stock worth $8,249,000 after buying an additional 827,257 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.